BAL 19403

Drug Profile

BAL 19403

Alternative Names: BAL19403

Latest Information Update: 06 Jul 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Basilea Pharmaceutica
  • Class Anti-inflammatories; Antiacnes; Macrolides; Skin disorder therapies
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acne; Bacterial infections

Most Recent Events

  • 01 Oct 2007 Phase-I clinical trials in Acne in Switzerland (Topical)
  • 01 Oct 2007 Phase-I clinical trials in Bacterial infections in Switzerland (Topical)
  • 01 Oct 2007 Data presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics (ICAAC-2007) added to the adverse events, pharmacokinetics, and Bacterial Infections pharmacodynamics sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top